Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Aastrom Adds Revenues Through $6.5M Regen Med Buy From Sanofi

This article was originally published in The Pink Sheet Daily

Executive Summary

The stem cell company will use revenues from the already-marketed products to continue funding the late-stage stem cell therapy in its pipeline and help it build out its commercial organization.

You may also be interested in...



Biopharma Dealmaking Quarterly Statistics, Q2 2014

Biopharma financing totaled $7.2 billion, a 36% decrease from Q1; 36 completed M&As had a combined potential value reaching $116 billion, more than three-and-a-half times the previous quarter; 84 biopharma alliances, together totaling $7.7 billion in potential pre-commercialization value, showed a significant jump from Q1’s $1.9 billion aggregate.

Deal Watch: Much Activity Beyond GSK/Novartis/Lilly Pacts And Valeant/Allergan Bid

In addition to the mega-deal, Valeant’s latest acquisition gambit and the Pfizer/AstraZeneca rumors, the hectic week saw Celgene pay a huge upfront for a Phase III Crohn’s candidate, Aastrom purchase Sanofi’s regenerative medicine business and The Medicines Company add to its surgical products portfolio.

Aastrom Stands Behind Its Decision To Shift Gears In Late Stages

The Michigan biotech is undergoing a complete restructuring as it cans its lead program and new management implements a different vision for the company.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS077112

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel